Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to "Standard of Care" Insulin in Basal Insulin Treated Patients With Uncontrolled Type 2 Diabetes Mellitus, With Six-Month Extension
Brief Summary: Primary Objective:

To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy as measured by glycated hemoglobin (HbA1c) change

Secondary Objectives:

* To demonstrate superiority of Toujeo versus "standard of care" basal insulin if non-inferiority criterion is met, measured by HbA1c change.
* To compare Toujeo to other "standard of care" basal insulin in terms of patient persistence with assigned basal insulin therapy with or without intensification.
* Risk of hypoglycemia including documented, symptomatic hypoglycemia (≤70 mg/dL) or severe (according to ADA Working Group).
* Change in fasting plasma glucose (FPG).
* Change in body weight.
* Differences in patient reported outcomes measured by Diabetes Treatment Satisfaction Questionnaire Status and Change versions (DTSQs and DTSQc).
* Change in hypoglycemic control subscale (HCS).
* Healthcare resource utilization including hospitalizations and emergency department or other health care provider visits and healthcare costs.


Options:
A: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
B: Arm Label: NPH insulin + insulin glulisine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nph insulin, Drug: Insulin glulisine | Arm Label: NPH insulin + human insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin | Arm Label: Insulin glargine + insulin glulisine; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine, Drug: Insulin glulisine | Arm Label: Insulin Glargine + Human insulin; Type: EXPERIMENTAL; Interventions: Drug: human insulin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: nph insulin; Assigned to Arm(s): NPH insulin + insulin glulisine | Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): Insulin Glargine + Human insulin, NPH insulin + human insulin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine + Human insulin, Insulin glargine + insulin glulisine | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): Insulin glargine + insulin glulisine, NPH insulin + insulin glulisine
C: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
D: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin

Answer: A